Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB204 PK and safety in adolescents with acne
NCT02801903Phase 1Completed
- Sponsor
- Novan
- Start
- Jun 2016
- Primary completion
- Aug 2016
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berdazimer in acne vulgaris, sponsored by Novan. Primary endpoints: Maximum observed plasma concentration of hMAP3 at Day 21 and Area under the plasma concentration time curve for hMAP3 at Day 21. Started Jun 2016; status: completed.
02
Drugs
berdazimer
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT02801903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02801903.